FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac Patients

NCT05020483 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Patient population changed and no subjects eligible for the study.

Conditions

Cardiac Disease

Interventions

DRUG: FEIBA
DRUG: Placebo

Sponsor

Mayo Clinic